BUZZ-Drug developer Schrodinger up after BofA upgrades to 'buy'

Reuters12-16
BUZZ-Drug developer Schrodinger up after BofA upgrades to 'buy'

** Shares of drug developer Schrodinger SDGR.O up about 1% at $18.24

** BofA upgrades stock to "buy" from "neutral"

** Brokerage sees a more favorable backdrop for the pharma sector and R&D spending

** Recent quarterly results underscore resilience despite market noise, with Software and Drug Discovery revenues consistently topping Wall Street expectations

** Remains positive on R&D rebound, believes it could accelerate adoption of SDGR's platform, even as near-term pharma budget pressures have weighed on Software segment growth

** 3 of 9 brokerages rate the stock "buy" or higher, 4 "hold", 2 brokerages rate the stock "sell" or higher; median PT is $28 - data compiled by LSEG

** As of last close, stock down ~6% YTD

(Reporting by Koyena Das from Bengaluru)

((Koyena.das@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment